GW PHARM.

• 23/05/12

  Director/PDMR Shareholding

• 22/05/12

  Third Cancer Pain Trial Commences

• 22/05/12

  Interim Results

• 08/05/12

  Successful completion of MRP for Sativex

• 26/04/12

  Notice of Results

• 23/04/12

  Sativex phase IIb pain trial results publication

• 16/04/12

  Almirall Milestone

• 05/04/12

  Board Changes

• 02/04/12

  Director/PDMR Shareholding

• 30/03/12

  Director/PDMR Shareholding

• 

  30/01/06

  GW Pharmaceuticals: 2007 a pivotal year.

  Despite the hurdles, GW has made considerable progress in developing the drug pipeline. Sativex was approved in Canada in 2005 as a treatment for symptomatic relief of neuropathic pain in adults.

• 22/11/11

  GW Pharmaceuticals says Sativex sales top expectations, but full year profit drops

• 08/06/11

  GW Pharma launches Sativex in Denmark after law change

• 26/05/11

  GW Pharma to launch MS treatment in Germany after regulatory approval

• 15/04/11

  GW Pharma receives Czech approval for Sativex spray for MS

• 06/08/09

  GW Pharmaceuticals finds a new supporter: Great Point Partners Healthcare Fund

• 17/10/07

  Sativex study boosts GW Pharma

Connect with Facebook to view or add comments for this company